Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
-SIVEXTRO® adds revenue generating product creating additional scale and synergies-
-Relaunch of XENLETA® and SIVEXTRO planned with targeted in-person promotion-
-Conference call today at
“We have been actively building the foundation for relaunching our commercial efforts in the community. Nabriva now has an experienced contract sales partner and the opportunity to promote and distribute an important new revenue-generating product in SIVEXTRO. Adding SIVEXTRO to our portfolio is an important component of our strategy to actively pursue business development and licensing opportunities that have a highly complementary customer base and leverage Nabriva’s capabilities,” said
CORPORATE AND DEVELOPMENT UPDATES
July 28, 2020, Nabriva announced that the European Commission(EC) approved the marketing authorization application for XENLETA (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults in the European Unionfollowing a review by the European Medicines Agency.
July 16, 2020, Nabriva announced that Sunovion Pharmaceuticals Canada Inc., received approval from Health Canadato market oral and intravenous (IV) formulations of XENLETA for the treatment of community-acquired pneumonia in adults in Canada. Nabriva entered into a license and commercialization agreement in March 2019with Sunovion Pharmaceuticals Canada Inc.for XENLETA in Canada.
July 15, 2020, Nabriva announced that it entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United Statesand certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial. In addition, Nabriva engaged Amplity Health, a leading pharmaceutical contract commercial organization, to provide community-based commercial and sales services for SIVEXTRO and XENLETA in the United States.
June 30, 2020, Nabriva announced that it had signed an exclusive agreement with WEP Clinical (WEP), a specialist pharmaceutical services company, to supply XENLETA on a named patient or expanded access basis in certain countries outside of the U.S., Chinaand Canada. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available and have an unmet medical need.
June 19, 2020, Nabriva received a Complete Response Letter (CRL) from the U.S. Food and Drug Administrationfor the New Drug Application (NDA) resubmission seeking marketing approval of CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis. Although Nabriva’s European contract manufacturing partners were prepared for regulatory authority inspections, the CRL cites observations at its manufacturing partners that could not be resolved due to FDA’s inability to conduct onsite inspections because of travel restrictions caused by the COVID-19 pandemic. In general, previously identified product quality and facility inspection related observations at its contract manufacturing partners are required to be satisfactorily resolved before the NDA may be approved. The FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the CRL. Nabriva plans to request a Type A meeting with the FDA to discuss its plans for completing foreign facility inspections and the appropriate next steps to refile the NDA. CONTEPO has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of serious infections, including cUTIs.
May 29, 2020, Nabriva announced that it entered into a definitive agreement with several healthcare-focused institutional investors, including Fidelity Management & Research Company, LLC, to issue and sell ordinary shares and warrants in a registered direct offering priced at-the-market under Nasdaq rules for aggregate gross proceeds of $38.0 millionbefore deducting placement agent fees and other offering expenses payable by Nabriva.
April 7, 2020, Nabriva announced it was restructuring its hospital-based commercial sales force and transitioning to a community-based sales force. The restructuring aligns the capabilities of the Company’s sales force with its strategic refocus for promoting XENLETA to community health care professionals, the excellent managed care coverage it has secured and its business development strategy to in-license additional community products, resulting in a substantial reduction in expenditures. In the second quarter, Nabriva also reduced commercial, medical affairs and administrative expenses.
April 9, 2020, Nabriva received confirmation from the Centers for Medicare and Medicaid Services(CMS) of a preliminary decision to assign permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for XENLETA 150 mg injection. The new billing code, J0691 Injection, became effective July 1, 2020, replaced the C Code, C9054 and enables healthcare providers to list physician-administered drugs on claim forms submitted to CMS to receive proper reimbursement for Medicare-eligible patients.
April 29, 2020, Nabriva received written notice from Nasdaq indicating that, based on the closing bid for the last 30 consecutive business days, the Company was not in compliance with the $1.00minimum bid price (Bid Price Rule) requirement for continued listing on The Nasdaq Global Select Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasdaq Global Select Market. Nabriva will have until December 28, 2020to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of Nabriva’s ordinary shares must be at least $1.00per share for a minimum of ten consecutive business days on or before December 28, 2020. At its July 29, 2020Annual General Meeting, Nabriva’s shareholders approved a reverse stock split (i.e., a consolidation of share capital under Irish law), subject to and conditional upon the board of directors determining, in its sole discretion, that a reverse stock split is necessary for the Company to comply with the Bid Price Rule, whereby every 10 ordinary shares of $0.01(nominal value) each in the authorized and unissued and authorized and issued share capital of the Company be consolidated into 1 ordinary share of $0.10(nominal value) each, and the subsequent reduction in the nominal value of the ordinary shares in the authorized and unissued and authorized and issued share capital of the Company from $0.10each to $0.01each. Nabriva’s board of directors is evaluating whether a reverse stock split is necessary.
Three Months Ended
- Revenues were
$0.5 millionfor the three months ended June 30, 2019and $0.5 millionfor the three months ended June 30, 2020, primarily due to grant revenues. For the three months ended June 30, 2020we recorded $0.1 millionof product revenue, net of gross-to-net accruals. In addition, we recorded a $0.3 millionreturns reserve adjustment for slow moving inventory, representing 50% of XENLETA IV inventory held at our Specialty Distributors, partly offset by a favorable $0.2 milliongross-to-net adjustment, resulting in $48 thousandof negative product revenue, net for the three months ended June 30, 2020.
- Research and development expenses decreased by
$1.6 millionfrom $8.1 millionfor the three months ended June 30, 2019to $6.5 millionfor the three months ended June 30, 2020. The decrease was primarily due to a $0.9 milliondecrease in staff costs, a $0.5 milliondecrease in research consulting fees, and a $0.1 milliondecrease in travel costs.
- Selling, general and administrative expense decreased by
$5.3 millionfrom $13.4 millionfor the three months ended June 30, 2019to $8.1 millionfor the three months ended June 30, 2020. The decrease was primarily due to a $4.5 milliondecrease in advisory and external consultancy expenses primarily related to pre-commercialization activities and professional service fees in 2019, a $0.5 milliondecrease in staff costs due to the termination of employees, a $0.4 milliondecrease in travel expenses and a $0.4 milliondecrease in infrastructure costs, partly offset by a $0.4 millionincrease in legal fees.
Six Months Ended
- Revenues decreased by
$1.0 millionfrom $2.2 millionfor the six months ended June 30, 2019to $1.3 millionfor the six months ended June 30, 2020, primarily due a $0.8 milliondecrease in collaboration revenue and a $0.2 milliondecrease in grant revenue, offset by a $0.1 millionincrease in product revenue, net associated with the launch of XENLETA. For the six months ended June 30, 2020, we recorded $0.2 millionof product revenue, net of gross-to-net accruals. In addition, we recorded a $0.3 millionreturns reserve adjustment for slow moving inventory, representing 50% of XENLETA IV inventory held at our Specialty Distributors, partly offset by a favorable $0.2 milliongross-to-net adjustment, resulting in $0.1 millionproduct revenue, net for the six months ended June 30, 2020.
- Research and development expenses decreased by
$4.2 millionfrom $15.6 millionfor the six months ended June 30, 2019to $11.4 millionfor the six months ended June 30, 2020. The decrease was primarily due to a $3.0 milliondecrease in research materials and purchased services related to the development of XENLETA, a $1.7 milliondecrease in research consulting fees, a $1.8 milliondecrease in staff costs and a $0.2 milliondecrease in travel and infrastructure costs, partly offset by a $2.6 millionrefund of NDA filing fees for our product candidate, CONTEPO, in 2019.
- Selling, general and administrative expense decreased by
$2.7 millionfrom $26.8 millionfor the six months ended June 30, 2019to $24.1 millionfor the six months ended June 30, 2020. The decrease was primarily due to a $5.2 milliondecrease in advisory and external consultancy expenses primarily related to pre-commercialization activities and professional service fees in 2019, a $0.7 milliondecrease in stock-based compensation expense and a $0.1 milliondecrease in other corporate costs, partly offset by a $0.3 millionincrease in legal fees and a $3.0 millionincrease in staff costs due to the addition of employees, prior to our reduction in sales force in April 2020.
- As previously disclosed, Nabriva’s distribution partners continue to primarily utilize their existing inventory to satisfy product demand, which in turn impacted sales in the second quarter of 2020. In light of the COVID-19 pandemic, the associated disruption to the healthcare delivery and the uncertainty of resuming full direct physician medical education and promotion, future sales amounts in 2020 are uncertain.
- As of
June 30, 2020, Nabriva Therapeutics had $49.7 millionin cash and cash equivalents, compared to $86.0 millionas of December 31, 2019.
- Based on its current operating plans, the Company expects that its existing cash resources will be sufficient to enable Nabriva to fund its operating expenses, debt service obligations and capital expenditure requirements into the first quarter of 2021. This estimate assumes, among other things, that Nabriva remains in compliance with the covenants under its Loan Agreement.
Please refer to our Annual Report on Forms 10-K for the fiscal year ended
Company to Host Conference Call
Nabriva’s management will host a conference call today at
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received
XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETA’s binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP. In these trials, XENLETA was compared with moxifloxacin and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. The most common adverse reactions associated with XENLETA included diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and vomiting. For more information, please visit www.xenleta.com.
INDICATION AND IMPORTANT SAFETY INFORMATION
XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
XENLETA is contraindicated in patients with known hypersensitivity to XENLETA or pleuromutilins.
XENLETA tablets are contraindicated for use with CYP3A4 substrates that prolong the QT interval.
WARNINGS AND PRECAUTIONS
XENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval.
Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.
Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including XENLETA, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
The most common adverse reactions (≥2%) for (a) XENLETA Injection are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache and (b) XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme elevation.
USE IN SPECIFIC POPULATIONS
In patients with severe hepatic impairment, reduce the dosage of XENLETA Injection to 150 mg infused over 60 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations.
Avoid XENLETA Injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA.
Avoid XENLETA Tablets with strong CYP3A or P-gp inhibitors.
Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets.
XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose.
To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact
Please see Full Prescribing Information for XENLETA.
Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully launch and commercialize XENLETA for the treatment of CABP, including the availability of and ease of access to XENLETA through major
Nabriva Therapeutics plc
|Consolidated Balance Sheets (unaudited)|
|As of||As of|
|(in thousands, except share data)|
|Cash and cash equivalents||$||86,019||$||49,660|
|Accounts receivable, net and other receivables||2,744||3,228|
|Total current assets||91,170||62,409|
|Property, plant and equipment, net||2,474||2,176|
|Intangible assets, net||91||97|
|Liabilities and equity|
|Accrued expense and other current liabilities||11,966||8,376|
|Total current liabilities||16,639||10,996|
|Other non-current liabilities||1,698||2,116|
|Total non-current liabilities||36,200||9,593|
|Ordinary shares, nominal value
|Preferred shares, par value
|Additional paid in capital||517,044||558,446|
|Accumulated other comprehensive income||27||27|
|Total stockholders’ equity||41,274||44,461|
|Total liabilities and stockholders’ equity||$||94,113||$||65,050|
|Consolidated Statements of Operations (unaudited)|
|Three Months Ended||Six Months Ended|
|(in thousands, except share and per share data)||2019||2020||2019||2020|
|Product revenue, net||$||—||(48||)||$||—||$||108|
|Research premium and grant revenue||525||528||1,228||1,016|
|Cost of product sales||—||(368||)||—||(376||)|
|Research and development expenses||(8,074||)||(6,500||)||(15,612||)||(11,444||)|
|Selling, general and administrative expenses||(13,427||)||(8,072||)||(26,836||)||(24,097||)|
|Total operating expenses||(21,501||)||(14,940||)||(42,448||)||(35,917||)|
|Loss from operations||(20,976||)||(14,453||)||(40,220||)||(34,641||)|
|Other income (expense):|
|Other income (expense), net||56||(634||)||126||164|
|Loss on extinguishment of debt||—||—||—||(2,757||)|
|Loss before income taxes||(21,752||)||(15,322||)||(41,815||)||(38,429||)|
|Income tax benefit (expense)||45||(119||)||(109||)||(271||)|
|Loss per share|
|Basic and diluted ($ per share)||$||(0.30||)||$||(0.14||)||$||(0.59||)||$||(0.37||)|
|Weighted average number of shares:|
|Basic and diluted||72,526,441||112,778,258||70,624,583||103,686,706|
|Condensed Consolidated Statements of Cash Flows
|Six Months Ended
|Net cash provided by (used in):|
|Effects of foreign currency translation on cash and cash equivalents||40||(70||)|
|Net decrease in cash and cash equivalents||(28,259||)||(36,522||)|
|Cash and cash equivalents and restricted cash at beginning of period||102,003||86,411|
|Cash and cash equivalents and restricted cash at end of period||$||73,744||$||49,889|
Source: Nabriva Therapeutics US, Inc